News
-
August 25, 2023
C-Path is pleased to welcome Acurex Biosciences as the newest member joining its Critical Path for Parkinson’s Consortium
AcureX is a pharmaceutical company on a mission to stop major neurodegenerative diseases before they start, with an initial focus on Parkinson’s disease. To achieve this, AcureX leverages a first-in-class peripheral drug-responsive biomarker assays to molecularly define and segment patients in combination with novel disease-modifying therapeutics. AcureX is ushering in a new era of precision medicine... -
August 25, 2023
C-Path’s Role in IHI Call 4: Enhancing Rare Disease Clinical Trials
This memo outlines how C-Path can contribute as a key strategic regulatory partner to the Innovative Health Initiative’s (IHI) call 4, “Establishing novel approaches to improve clinical trials for rare and ultra-rare diseases.” We encourage potential partners to review the memo and reach out as early as possible to rdcadap@c-path.org with interest. On 27 July 2023, the... -
August 22, 2023
C-Path Welcomes ObvioHealth
C-Path is proud to welcome ObvioHealth, a virtual research organization (VRO), as the newest member of its Electronic Clinical Outcome Assessment (eCOA) Consortium. Comprised of 23 firms that provide electronic data collection technologies and services for capturing patient-reported outcome and other clinical outcome assessment data in clinical trials, eCOA Consortium members collaborate in a pre-competitive... -
July 25, 2023
PRO Consortium and eCOA Consortium Announce Publication of an Open Access Article
C-Path’s PRO Consortium and eCOA Consortium are pleased to announce the publication of an open access article in the Value in Health, titled “Best Practice Recommendations for Electronic Patient-Reported Outcome (ePRO) Dataset Structure and Standardization to Support Drug Development.” This article provides best practice recommendations covering the application of CDISC standards to maintain the integrity of ePRO datasets, reduce stakeholder burden,... -
July 20, 2023
TTC Announces Publication in Transplantation
C-Path’s Transplant Therapeutics Consortium is pleased to announce the recent publication in Transplantation by William Fitzsimmons and Maarten Naesens, “Acute Rejection After Kidney Transplant—An Endpoint Not Predictive of Treatment Effect on Graft Survival.” The article highlights the lack of consistent treatment effect of BPAR on graft survival and the work we are doing in TTC to improve upon the current...